Celcuity Inc.
CELC · Services-Medical Laboratories · 48.8M shares · +60%/yr ↑ dilution · EDGAR filings ↗
Reference price $137.00 · est. market cap ~$6.7B — last insider sale, 2026-05-04 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — oncology diagnostic+therapeutic clinical, heavy burn ($153M), funded.
Strengths
- Liquidity — current ratio 10.6 (88th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Chronic dilutionShare count +60%/yr over 2y (dilution, book value/share -72%)
- Cash burnNegative free cash flow (-153.5M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Exec changeRecent 8-K item 5.02 8-K ↗
- Trial resultPositive trial readout — primary endpoint met (8-K) 8-K ↗
- Strong balance sheetStrong balance sheet — $441M cash & investments, ~12 quarters of runway
- Insider sellingInsider selling — 10 open-market sale(s) by 2 insider(s) (cluster of 2 insiders, ~$8M, last 6mo) Form 4 ↗
- Trial readout soonUpcoming trial readout ~2026-06-30 — PHASE3 · Breast Cancer
- Notable holderHeld by 4 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC +1 more (as of 2026-03-31)
Key metrics
Return on equity
-176.1%
Return on assets
-37.9%
ROIC
-57.1%
Debt / equity
1.4×
Current ratio
10.5×
Free cash flow
-$154M
Tangible book value
$101M
Cash & investments
$441M
Cash runway
12q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-05 | Murphy Polly A. | Grant | 1.5K | — |
| 2026-06-05 | ROMP CHARLES R | Grant | 1.5K | — |
| 2026-06-05 | Furcht Leo | Grant | 1.5K | — |
| 2026-06-05 | Buller Richard E | Grant | 1.5K | — |
| 2026-06-05 | Dalvey David | Grant | 1.5K | — |
| 2026-06-05 | NIGON RICHARD | Grant | 1.5K | — |
| 2026-06-02 | Laing Lance G. | Option exercise | 1.0K | $9.89 |
| 2026-05-19 | Buller Richard E | Gift | 1.0K | — |
| 2026-05-19 | Buller Richard E | Gift | 1.0K | — |
| 2026-05-04 | Buller Richard E | Option exercise | 9.0K | $5.10 |
| 2026-05-04 | Buller Richard E | Sell | 1.3K | $137.00 |
| 2026-05-04 | Buller Richard E | Sell | 550 | $139.00 |
| 2026-05-04 | Buller Richard E | Sell | 1.7K | $139.58 |
| 2026-05-04 | Buller Richard E | Sell | 2.3K | $141.03 |
| 2026-05-04 | Buller Richard E | Sell | 2.8K | $142.04 |
| 2026-05-04 | Buller Richard E | Sell | 365 | $143.24 |
| 2026-05-04 | Dalvey David | Sell | 25K | $140.68 |
| 2026-04-09 | NIGON RICHARD | Gift | 10K | — |
| 2026-03-31 | Buller Richard E | Option exercise | 3.0K | $5.10 |
| 2026-03-31 | Buller Richard E | Sell | 2.3K | $110.11 |
| 2026-03-31 | Buller Richard E | Sell | 675 | $110.83 |
| 2026-02-11 | ROMP CHARLES R | Grant | 215 | — |
| 2026-01-27 | Dalvey David | Sell | 20K | $120.03 |
| 2025-12-15 | NIGON RICHARD | Gift | 20K | — |
| 2025-12-05 | Buller Richard E | Option exercise | 3.0K | $5.50 |
| 2025-12-05 | Buller Richard E | Sell | 1.5K | $105.34 |
| 2025-12-05 | Buller Richard E | Sell | 1.5K | $106.04 |
| 2025-12-04 | Furcht Leo | Option exercise | 250 | $7.60 |
| 2025-12-02 | Buller Richard E | Gift | 500 | — |
| 2025-12-01 | Buller Richard E | Option exercise | 1.1K | $14.83 |
| 2025-12-01 | Buller Richard E | Sell | 1.1K | $98.13 |
| 2025-11-21 | Dalvey David | Sell | 15K | $100.00 |
| 2025-11-20 | Buller Richard E | Option exercise | 3.9K | $14.83 |
| 2025-11-20 | Buller Richard E | Sell | 3.9K | $96.73 |
| 2025-11-19 | Buller Richard E | Gift | 500 | — |
| 2025-09-11 | NIGON RICHARD | Option exercise | 4.7K | $7.56 |
| 2025-09-11 | NIGON RICHARD | Option exercise | 3.2K | $7.56 |
| 2025-09-08 | BAKER BROS. ADVISORS LP | Buy | 14K | $56.22 |
| 2025-09-08 | BAKER BROS. ADVISORS LP | Buy | 152K | $56.22 |
| 2025-09-08 | BAKER BROS. ADVISORS LP | Buy | 388 | $58.02 |
| 2025-09-08 | BAKER BROS. ADVISORS LP | Buy | 4.2K | $58.02 |
| 2025-09-02 | Sullivan Brian F. | Option exercise | 104K | $8.05 |
| 2025-07-28 | Dalvey David | Sell | 2.0K | $46.05 |
| 2025-07-28 | Dalvey David | Sell | 3.1K | $44.36 |
| 2025-07-28 | Dalvey David | Sell | 4.2K | $45.24 |
| 2025-07-28 | Dalvey David | Sell | 57K | $43.30 |
| 2025-07-28 | Dalvey David | Sell | 22K | $44.36 |
| 2025-07-28 | Dalvey David | Sell | 16K | $45.29 |
| 2025-07-28 | Dalvey David | Sell | 4.1K | $46.05 |
| 2025-05-27 | Buller Richard E | Gift | 1.1K | — |
| 2025-05-27 | Buller Richard E | Gift | 1.1K | — |
| 2025-05-19 | Buller Richard E | Grant | 1.0K | — |
| 2025-04-14 | Sullivan Brian F. | Gift | 8.2K | — |
| 2025-04-14 | Sullivan Brian F. | Gift | 8.2K | — |
| 2025-03-04 | Sullivan Brian F. | Gift | 37K | — |
| 2025-03-04 | Sullivan Brian F. | Gift | 37K | — |
| 2025-03-03 | Sullivan Brian F. | Gift | 45K | — |
| 2025-03-03 | Sullivan Brian F. | Gift | 45K | — |
| 2025-03-03 | Sullivan Brian F. | Gift | 40K | — |
| 2025-03-03 | Sullivan Brian F. | Gift | 40K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06757634 ↗ | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) Breast Cancer | PHASE3 | Recruiting | 2029-03-31 |
| NCT06190899 ↗ | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male | PHASE1/PHASE2 | Recruiting | 2028-01-01 |
| NCT05501886 ↗ | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) Breast Cancer | PHASE3 | Active Not Recruiting | 2026-06-30 |
| NCT02684032 ↗ | A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer Breast Cancer | PHASE1 | Completed | 2022-01-19 |
| NCT05134922 ↗ | Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009 Breast Neoplasm Malignant Female | — | Available |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-08 | Material agreement1.02Debt obligationOtherExhibits | filing ↗ |
| 2026-06-02 | Reg FDOtherExhibits | filing ↗ |
| 2026-05-20 | Exec/director change | filing ↗ |
| 2026-05-18 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-05-14 | ResultsExhibits | filing ↗ |
| 2026-05-01 | Reg FDOtherExhibits | filing ↗ |
| 2026-03-25 | ResultsExhibits | filing ↗ |
| 2026-02-12 | Exec/director changeReg FDExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-08 | 2026-06-03 | 0001493152-26-027717 ↗ |
| 8-K | 2026-06-02 | 2026-06-02 | 0001493152-26-026761 ↗ |
| 8-K/A | 2026-05-20 | 2026-02-11 | 0001493152-26-024510 ↗ |
| 8-K | 2026-05-18 | 2026-05-18 | 0001493152-26-024175 ↗ |
| 10-Q | 2026-05-14 | 2026-03-31 | 0001493152-26-023180 ↗ |
| 8-K | 2026-05-14 | 2026-05-14 | 0001493152-26-023065 ↗ |
| 8-K | 2026-05-01 | 2026-05-01 | 0001493152-26-020918 ↗ |
| 10-K | 2026-03-26 | 2025-12-31 | 0001493152-26-012801 ↗ |
| 8-K | 2026-03-25 | 2026-03-25 | 0001493152-26-012668 ↗ |
| 8-K | 2026-02-12 | 2026-02-11 | 0001493152-26-006444 ↗ |
| 8-K | 2025-11-17 | 2025-11-17 | 0001493152-25-023897 ↗ |
| 10-Q | 2025-11-13 | 2025-09-30 | 0001493152-25-022401 ↗ |